<DOC>
	<DOC>NCT00857779</DOC>
	<brief_summary>The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ</brief_summary>
	<brief_title>Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>A clinical history of grass pollen induced allergic rhinoconjunctivitis of two years or more requiring treatment during the grass pollen season Lack of adequate relief with symptomatic medication during the previous grass pollen season Positive Skin Prick Test (SPT) response to Phleum pratense (wheal diameter &gt;= 3mm) currently performed or not older than 60 days before screening FEV1 &lt; 70% of predicted value at screening Bronchial asthma corresponding to GINA step 3 or more, even if controlled History of asthma exacerbation or emergency visit or admission for asthma in the previous 12 months Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years Exclusion criteria in accordance with contraindications in the SPC of ALKFlex SQ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>allergen immunotherapy</keyword>
	<keyword>allergy to grass pollen</keyword>
</DOC>